Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (6): 915-918    DOI: 10.12892/ejgo5145.2019
Review Previous articles | Next articles
Uterine fibroids: a new insight into an old problem
A. Markowska1, *(), W. Bednarek2, R. Jach3, A. Czekała4, J. Markowska5
1Department of Perinatology and women's Diseases, Poznań University of Medical Sciences, Poznań, Poland
2Medical University in Lublin, Lublin, Poland
3Department of Gynecology and Obstetrics, Jagiellonian University Medical College Gynecology and Obstetrics, Kraków, Poland
4Department of Pathomorphology and Clinical Immunology, Poznań University of Medical Sciences, Poznań, Poland
5Department of Oncological Gynecology, Clinical Hospital of Transfiguration, Poznań University of Medical Sciences, Poznań, Poland
Download:  PDF(282KB)  ( 235 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

With the development of molecular methods in cancer biology, the etiopathogenesis of commonly occurring uterine myomas is constantly subject to amendment. It was found that ovarian steroid hormones are involved in the development of these benign tumors, hence the development of new therapies using selective progesterone receptor modulators (uliprystal acetate, UPA), especially in combination with vitamin D3 supplementation. Genetic changes associated with the pathogenesis of myomas, especially mutations in MED12 and related signaling via Wnt / β catenin, may be precursors to the development of aggressive forms of these benign tumors and therefore be influential regarding treatment options. Studies have also revealed the role of microRNA overexpression and angiogenesis in the development of uterine myomas, the inhibition of which may be associated with future therapy of these tumors. In recent years, the role of stem cells (SCs) in myomas and pathways involved in their activation have been described, which may also have clinical implications in the future.

Key words:  Uterine fibroids      Steroid hormones      SPERMS      MED12 and HMGA mutations      Angiogenesis      Stem cells     
Published:  10 December 2019     
*Corresponding Author(s):  A. MARKOWSKA     E-mail:  annamarkowska@vp.pl

Cite this article: 

A. Markowska, W. Bednarek, R. Jach, A. Czekała, J. Markowska. Uterine fibroids: a new insight into an old problem. European Journal of Gynaecological Oncology, 2019, 40(6): 915-918.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo5145.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I6/915

[1] Marcin Jedryka, Agnieszka Chrobak, Anna Chelmonska-Soyta, Daria Fijalkowska, Rafal Matkowski. Decreased expression of estrogen receptors alpha and beta in peripheral blood lymphocytes from the endometrial cancer patients and women with endometriosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 375-379.
[2] D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.
[3] W. Wang, R. Chen, Y. Zhang, K.J. Zou, M.L. Ye, X.H. He, F. Zhang, J. Han, H.Y. Dong. Understanding the molecular link between SPOP gene expression and breast cancer stem cell[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1006-1009.
[4] A. Markowska, B. Kasprzak, K. Jaszczyńska-Nowinka, J. Markowska. Has the time come for therapy linked to cancer stem cells in ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 697-701.
[5] F. Barra, C. Bondi, C. Scala, V. G. Vellone, S. Ferrero. Pazopanib for the treatment of gynecological malignancies[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 702-708.
[6] A. Markowska, A. Huczyński, Z. Kojs, D. Twardawa, J. Markowska. Hypoxia and its importance in the course of gynaecological cancers[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 711-713.
[7] J. Zheng, P. Liu, C. Li, L. Cheng, Y. Xu, F. Guo, M. Xiong, T. Song, Y. Li, F. Yan, H. Xu, B. Chen, J. Zhang. Umbilical cord-derived mesenchymal stem cells efficiently induced apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 839-845.
[8] A. Markowska, S. Sajdak, J. Markowska, A. Huczyński. Could there be a role for the antidiabetic drug metformin in oncological treatment?[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 867-870.
[9] A. Markowska, S. Sajdak. Role of cancer stem cells and microRNA in resistance to chemotherapy in patients with ovarian cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 181-183.
[10] N. Kenda Šuster, I. Virant-Klun, S. Frković Grazio, Š. Smrkolj. The significance of the pluripotency and cancer stem cell-related marker NANOG in diagnosis and treatmentof ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 604-612.
No Suggested Reading articles found!